跳至主要内容
临床试验/NCT01292915
NCT01292915已完成不适用

Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,044 人开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
1,044
试验地点
1
主要终点
Rebleeding (within 7 days from the Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) episode)

研究概览

简要总结

The main aim of the study is to describes the outcomes of patients with Upper Gastrointestinal Bleed (UGIB) in a real-life setting. Additionally analyse assessed predictors of outcome, including the impact of hemostatic endoscopic and pharmacologic therapies.

详细描述

MSD

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (>=18yrs) admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia...
  • Evidence that an upper GI endoscopy was performed

排除标准

  • GI bleeding not from NVUGIB

结局指标

主要结局

Rebleeding (within 7 days from the Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) episode)

时间窗: 7 days

次要结局

  • Surgery due to re-bleeding(7 days)
  • Mortality due to bleeding(7 days)
  • Rebleeding in high risk peptic ulcer patients(7 days)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验